A significant study discovering the market avenues on, “Neurodegenerative Disorders Market Size, Share & Trends Analysis Report by Disease Type (Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Others), Drug Class, Route of Administration, Mechanism of Action, Stage of Disease, Patient Demographics, End-users, and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2026–2035” A holistic view of the market pathways in the neurodegenerative disorders market underscores revenue acceleration through three key levers scalable product line extensions, high‑maturity strategic partnerships.
Global Neurodegenerative Disorders Market Forecast 2035:
According to the report, the global neurodegenerative disorders market is projected to expand from USD 39.8 billion in 2025 to USD 69.9 billion by 2035, registering a CAGR of 5.8%, the highest during the forecast period. The neurodegenerative disorders market is witnessing significant growth, driven by the rising prevalence of conditions such as Alzheimer’s, Parkinson’s, and ALS, coupled with high unmet medical needs. Advances in therapeutics, including gene and cell therapies, monoclonal antibodies, and combination treatments, along with innovations in diagnostics and digital health technologies, are enabling earlier detection and more effective patient management.
Key drivers include increased patient awareness, integration of AI and biomarkers for precision medicine, strategic collaborations, and regulatory incentives such as orphan drug designations. However, market expansion faces challenges from complex disease biology, difficulties in drug delivery across the blood–brain barrier, high R&D costs, lengthy clinical trials, and patient recruitment hurdles. Overall, the market is poised for continued growth as companies focus on disease-modifying therapies, innovative treatment approaches, and enhanced patient care solutions.
“Key Driver, Restraint, and Growth Opportunity Shaping the Global Neurodegenerative Disorders Market”
The scarcity of effective treatments of progressive neurodegenerative diseases, including Alzheimer disease, Parkinson disease, and ALS, is a key factor in market expansion. The unmet need also motivates investment, research, and collaborations within the sector to motivate companies to come up with new drugs, digital health products and diagnostic solutions to enhance patient outcomes. An example is in 2025 NRG Therapeutics successfully raised an oversubscribed £50 million Series B funding to develop a Parkinson disease and ALS/MND therapeutic, following critical unmet medical necessities in which there are currently no disease-modifying therapies.
Patient recruitment and retention in neurodegenerative disease clinical trials is a major challenge because of the fast rate of progression of the disease, cognitive dysfunction, and small numbers due to general scarcity of patients, especially in rare disorders. These will contribute to a sluggish enrollment process, higher trial expenses, and longer development cycles, limiting the growth of neurodegenerative disorders markets as a whole.
A combination therapy is also a major opportunity in the market of neurodegenerative disorders; it involves combining two or more modalities of treatment (small molecule, biologic, gene or cell therapy, or digital therapy) and shows synergistic effects. As an example, NeuroSense Therapeutics, a company that is developing a combination therapy of multiple pathways in ALS called PrimeC, displayed new results of its Phase 2b trial at the 2025 annual meeting of the American Academy of Neurology (AAN).
Expansion of Global Neurodegenerative Disorders Market
“Innovation, and public funding propel the global Neurodegenerative Disorders market expansion”
- The neurodegenerative disorders market is expanding globally, owing to increased prevalence, early diagnosis programs, strategic alliances, regulatory policies on the rare diseases and multi-targeted and precision therapies. An example is the Biohaven ltd., which further the development of innovative treatment to rare neurodegenerative disorders, when in 2025, it announced that the FDA accepted its New Drug Application of Troriluzole to treat Spinocerebellar Ataxia (SCA) with Priority Review and the Orphan Drug Designation.
- Government and insurance incentives have the potential to significantly stimulate the adoption of the neurodegenerative disorders market by lowering the price of treatment, enhancing the provision of treatment to patients, reimbursement of new treatments and the research and development of new healthcare solutions. To illustrate, the NIH and HHS developed the National Plan to End Parkinson’s Act in 2025, making research and care efforts coordinated to improve access to treatment and support of Parkinson’s and other related neurodegenerative disorders.
Regional Analysis of Global Neurodegenerative Disorders Market
- North America's neurodegenerative disorders market is expected to increase due to rising prevalence of diseases like Alzheimer's and Parkinson's, as well as an aging population. The solid healthcare infrastructure in region, high diagnostic rates, and the quicker pace of changing innovative therapeutic measures facilitate consistent development of the market. In addition, the positive regulatory frameworks, significant investments in research, and the growing popularity of the early intervention and management of the disease make North America the dominant and the most vibrant region of the worldwide neurodegenerative disorder’s scenario.
- The neurodegenerative disorders market in Asia Pacific region is expected to develop the greatest due to rapid urbanization, shifting healthcare priorities, and increased funding in brain research. The growing clinical trial networks in the region, enabling regulatory reforms and focus on drug development that is affordable is creating a good market momentum, and the increased patient awareness and the adoption of digital health technologies are further increasing the pace of adoption in some of the most important emerging markets.
Prominent players operating in the global neurodegenerative disorders market are AbbVie Inc., Acorda Therapeutics, Inc., Amneal Pharmaceuticals LLC, AstraZeneca plc, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eisai Co., Ltd., Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Lundbeck A/S, Merck & Co., Inc., Novartis AG, Orion Corporation, Pfizer Inc., Roche Holding AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., and Other Key Players.
The global neurodegenerative disorders market has been segmented as follows:
Global Neurodegenerative Disorders Market Analysis, By Disease Type
- Alzheimer's Disease
- Parkinson's Disease
- Huntington's Disease
- Amyotrophic Lateral Sclerosis (ALS)
- Multiple Sclerosis (MS)
- Others
Global Neurodegenerative Disorders Market Analysis, By Drug Class
- Cholinesterase Inhibitors
- NMDA Receptor Antagonists
- Dopamine Agonists
- MAO-B Inhibitors
- COMT Inhibitors
- Immunomodulators
- Immunosuppressants
- Others
Global Neurodegenerative Disorders Market Analysis, By Route of Administration
- Oral
- Injectable
- Subcutaneous
- Intramuscular
- Intravenous
- Others
- Transdermal Patches
- Inhalation
Global Neurodegenerative Disorders Market Analysis, By Mechanism of Action
- Symptomatic Treatment
- Disease-Modifying Treatment
- Neuroprotective Agents
- Anti-inflammatory Agents
- Gene Therapy
- Cell Therapy
- Others
Global Neurodegenerative Disorders Market Analysis, By Stage of Disease
- Early Stage/Mild
- Moderate Stage
- Advanced/Severe Stage
- Preclinical/Prodromal
Global Neurodegenerative Disorders Market Analysis, By Patient Demographics
- Pediatric
- Adult
- Geriatric
Global Neurodegenerative Disorders Market Analysis, By End-users
- Hospitals & Clinics
- Diagnosis & Screening
- Disease Management
- Symptomatic Treatment
- Rehabilitation Services
- Emergency Care
- Inpatient Treatment
- Others
- Research & Academic Institutions
- Clinical Trials
- Drug Discovery & Development
- Biomarker Research
- Genetic Studies
- Epidemiological Studies
- Others
- Pharmaceutical & Biotechnology Companies
- Drug Manufacturing
- Biologics Production
- Gene Therapy Development
- Vaccine Development
- Clinical Development
- Others
- Diagnostic Laboratories
- Biomarker Testing
- Genetic Screening
- CSF Analysis
- Neuroimaging Services
- Pathology Services
- Others
- Home Healthcare Providers
- Long-term Care Management
- Medication Administration
- Patient Monitoring
- Rehabilitation Support
- Palliative Care
- Others
- Specialty Clinics
- Movement Disorder Clinics
- Memory Clinics
- ALS Clinics
- MS Centers
- Cognitive Assessment Centers
- Others
- Other End-users
Global Neurodegenerative Disorders Market Analysis, By Region
About Us
MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.
We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.
Contact Us
USA Address:
800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.
+1(302)303-2617
info@marketgenics.co
India Address:
3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.
sales@marketgenics.co
Table of Contents
- 1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
- 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
- 1.6.1. Open Sources
- 1.6.2. Paid Databases
- 1.6.3. Associations
- 1.7. Primary Research
- 1.7.1. Primary Sources
- 1.7.2. Primary Interviews with Stakeholders across Ecosystem
- 2. Executive Summary
- 2.1. Global Neurogenerative Disorders Market Outlook
- 2.1.1. Neurogenerative Disorders Market Size (Value - US$ Bn), and Forecasts, 2021-2035
- 2.1.2. Compounded Annual Growth Rate Analysis
- 2.1.3. Growth Opportunity Analysis
- 2.1.4. Segmental Share Analysis
- 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
- 2.5.1. Customer/ End-use Industry Assessment
- 2.5.2. Growth Opportunity Data, 2025-2035
- 2.5.2.1. Regional Data
- 2.5.2.2. Country Data
- 2.5.2.3. Segmental Data
- 2.5.3. Identification of Potential Market Spaces
- 2.5.4. GAP Analysis
- 2.5.5. Potential Attractive Price Points
- 2.5.6. Prevailing Market Risks & Challenges
- 2.5.7. Preferred Sales & Marketing Strategies
- 2.5.8. Key Recommendations and Analysis
- 2.5.9. A Way Forward
- 2.1. Global Neurogenerative Disorders Market Outlook
- 3. Industry Data and Premium Insights
- 3.1. Global Neurogenerative Disorders Industry Overview, 2025
- 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
- 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
- 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Technology Roadmap and Developments
- 3.4. Trade Analysis
- 3.4.1. Import & Export Analysis, 2025
- 3.4.2. Top Importing Countries
- 3.4.3. Top Exporting Countries
- 3.5. Trump Tariff Impact Analysis
- 3.5.1. Manufacturer
- 3.5.1.1. Based on the component & Raw material
- 3.5.2. Supply Chain
- 3.5.3. End Consumer
- 3.5.1. Manufacturer
- 3.6. Raw Material Analysis
- 3.1. Global Neurogenerative Disorders Industry Overview, 2025
- 4. Market Overview
- 4.1. Market Dynamics
- 4.1.1. Drivers
- 4.1.1.1. Aging population & rising disease prevalence
- 4.1.1.2. Advances in gene/cell therapies and biomarkers
- 4.1.1.3. Rising R&D investment and regulatory incentives
- 4.1.2. Restraints
- 4.1.2.1. Complex biology (blood–brain barrier) and long clinical timelines
- 4.1.2.2. High development costs and uncertain reimbursement
- 4.1.1. Drivers
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
- 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
- 4.3.2. Tariffs and Standards
- 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Ecosystem Analysis
- 4.5. Porter’s Five Forces Analysis
- 4.6. PESTEL Analysis
- 4.7. Global Neurogenerative Disorders Market Demand
- 4.7.1. Historical Market Size - in Value (US$ Bn), 2020-2024
- 4.7.2. Current and Future Market Size - in Value (US$ Bn), 2026–2035
- 4.7.2.1. Y-o-Y Growth Trends
- 4.7.2.2. Absolute $ Opportunity Assessment
- 4.1. Market Dynamics
- 5. Competition Landscape
- 5.1. Competition structure
- 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
- 5.2.1. Global Company Market Share
- 5.2.2. By Region
- 5.2.2.1. North America
- 5.2.2.2. Europe
- 5.2.2.3. Asia Pacific
- 5.2.2.4. Middle East
- 5.2.2.5. Africa
- 5.2.2.6. South America
- 5.3. Product Comparison Matrix
- 5.3.1. Specifications
- 5.3.2. Market Positioning
- 5.3.3. Pricing
- 5.1. Competition structure
- 6. Global Neurogenerative Disorders Market Analysis, By Disease Type
- 6.1. Key Segment Analysis
- 6.2. Neurogenerative Disorders Market Size (Value - US$ Bn), Analysis, and Forecasts, By Disease Type, 2021-2035
- 6.2.1. Alzheimer's Disease
- 6.2.2. Parkinson's Disease
- 6.2.3. Huntington's Disease
- 6.2.4. Amyotrophic Lateral Sclerosis (ALS)
- 6.2.5. Multiple Sclerosis (MS)
- 6.2.6. Others
- 7. Global Neurogenerative Disorders Market Analysis, By Drug Class
- 7.1. Key Segment Analysis
- 7.2. Neurogenerative Disorders Market Size (Value - US$ Bn), Analysis, and Forecasts, By Drug Class, 2021-2035
- 7.2.1. Cholinesterase Inhibitors
- 7.2.2. NMDA Receptor Antagonists
- 7.2.3. Dopamine Agonists
- 7.2.4. MAO-B Inhibitors
- 7.2.5. COMT Inhibitors
- 7.2.6. Immunomodulators
- 7.2.7. Immunosuppressants
- 7.2.8. Others
- 8. Global Neurogenerative Disorders Market Analysis and Forecasts,By Route of Administration
- 8.1. Key Findings
- 8.2. Neurogenerative Disorders Market Size (Value - US$ Mn), Analysis, and Forecasts, By Route of Administration, 2021-2035
- 8.2.1. Oral
- 8.2.2. Injectable
- 8.2.2.1. Subcutaneous
- 8.2.2.2. Intramuscular
- 8.2.2.3. Intravenous
- 8.2.2.4. Others
- 8.2.3. Transdermal Patches
- 8.2.4. Inhalation
- 9. Global Neurogenerative Disorders Market Analysis and Forecasts, By Mechanism of Action
- 9.1. Key Findings
- 9.2. Neurogenerative Disorders Market Size (Vo Value - US$ Mn), Analysis, and Forecasts, By Mechanism of Action, 2021-2035
- 9.2.1. Symptomatic Treatment
- 9.2.2. Disease-Modifying Treatment
- 9.2.3. Neuroprotective Agents
- 9.2.4. Anti-inflammatory Agents
- 9.2.5. Gene Therapy
- 9.2.6. Cell Therapy
- 9.2.7. Others
- 10. Global Neurogenerative Disorders Market Analysis and Forecasts, By Stage of Disease
- 10.1. Key Findings
- 10.2. Neurogenerative Disorders Market Size (Value - US$ Mn), Analysis, and Forecasts, By Stage of Disease, 2021-2035
- 10.2.1. Early Stage/Mild
- 10.2.2. Moderate Stage
- 10.2.3. Advanced/Severe Stage
- 10.2.4. Preclinical/Prodromal
- 11. Global Neurogenerative Disorders Market Analysis and Forecasts, By Patient Demographics
- 11.1. Key Findings
- 11.2. Neurogenerative Disorders Market Size (Value - US$ Mn), Analysis, and Forecasts, By Patient Demographics, 2021-2035
- 11.2.1. Pediatric
- 11.2.2. Adult
- 11.2.3. Geriatric
- 12. Global Neurogenerative Disorders Market Analysis and Forecasts, By End-users
- 12.1. Key Findings
- 12.2. Neurogenerative Disorders Market Size (Value - US$ Mn), Analysis, and Forecasts, By End-users, 2021-2035
- 12.2.1. Hospitals & Clinics
- 12.2.1.1. Diagnosis & Screening
- 12.2.1.2. Disease Management
- 12.2.1.3. Symptomatic Treatment
- 12.2.1.4. Rehabilitation Services
- 12.2.1.5. Emergency Care
- 12.2.1.6. Inpatient Treatment
- 12.2.1.7. Others
- 12.2.2. Research & Academic Institutions
- 12.2.2.1. Clinical Trials
- 12.2.2.2. Drug Discovery & Development
- 12.2.2.3. Biomarker Research
- 12.2.2.4. Genetic Studies
- 12.2.2.5. Epidemiological Studies
- 12.2.2.6. Others
- 12.2.3. Pharmaceutical & Biotechnology Companies
- 12.2.3.1. Drug Manufacturing
- 12.2.3.2. Biologics Production
- 12.2.3.3. Gene Therapy Development
- 12.2.3.4. Vaccine Development
- 12.2.3.5. Clinical Development
- 12.2.3.6. Others
- 12.2.4. Diagnostic Laboratories
- 12.2.4.1. Biomarker Testing
- 12.2.4.2. Genetic Screening
- 12.2.4.3. CSF Analysis
- 12.2.4.4. Neuroimaging Services
- 12.2.4.5. Pathology Services
- 12.2.4.6. Others
- 12.2.5. Home Healthcare Providers
- 12.2.5.1. Long-term Care Management
- 12.2.5.2. Medication Administration
- 12.2.5.3. Patient Monitoring
- 12.2.5.4. Rehabilitation Support
- 12.2.5.5. Palliative Care
- 12.2.5.6. Others
- 12.2.6. Specialty Clinics
- 12.2.6.1. Movement Disorder Clinics
- 12.2.6.2. Memory Clinics
- 12.2.6.3. ALS Clinics
- 12.2.6.4. MS Centers
- 12.2.6.5. Cognitive Assessment Centers
- 12.2.6.6. Others
- 12.2.7. Other End-users
- 12.2.1. Hospitals & Clinics
- 13. Global Neurogenerative Disorders Market Analysis and Forecasts, by Region
- 13.1. Key Findings
- 13.2. Neurogenerative Disorders Market Size (Value - US$ Mn), Analysis, and Forecasts, by Region, 2021-2035
- 13.2.1. North America
- 13.2.2. Europe
- 13.2.3. Asia Pacific
- 13.2.4. Middle East
- 13.2.5. Africa
- 13.2.6. South America
- 14. North America Neurogenerative Disorders Market Analysis
- 14.1. Key Segment Analysis
- 14.2. Regional Snapshot
- 14.3. North America Neurogenerative Disorders Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 14.3.1. Disease Type
- 14.3.2. Drug Class
- 14.3.3. Route of Administration
- 14.3.4. Mechanism of Action
- 14.3.5. Stage of Disease
- 14.3.6. Patient Demographics
- 14.3.7. End-Users
- 14.3.8. Country
- 14.3.8.1. USA
- 14.3.8.2. Canada
- 14.3.8.3. Mexico
- 14.4. USA Neurogenerative Disorders Market
- 14.4.1. Country Segmental Analysis
- 14.4.2. Disease Type
- 14.4.3. Drug Class
- 14.4.4. Route of Administration
- 14.4.5. Mechanism of Action
- 14.4.6. Stage of Disease
- 14.4.7. Patient Demographics
- 14.4.8. End-Users
- 14.5. Canada Neurogenerative Disorders Market
- 14.5.1. Country Segmental Analysis
- 14.5.2. Disease Type
- 14.5.3. Drug Class
- 14.5.4. Route of Administration
- 14.5.5. Mechanism of Action
- 14.5.6. Stage of Disease
- 14.5.7. Patient Demographics
- 14.5.8. End-Users
- 14.6. Mexico Neurogenerative Disorders Market
- 14.6.1. Country Segmental Analysis
- 14.6.2. Disease Type
- 14.6.3. Drug Class
- 14.6.4. Route of Administration
- 14.6.5. Mechanism of Action
- 14.6.6. Stage of Disease
- 14.6.7. Patient Demographics
- 14.6.8. End-Users
- 15. Europe Neurogenerative Disorders Market Analysis
- 15.1. Key Segment Analysis
- 15.2. Regional Snapshot
- 15.3. Europe Neurogenerative Disorders Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 15.3.1. Disease Type
- 15.3.2. Drug Class
- 15.3.3. Route of Administration
- 15.3.4. Mechanism of Action
- 15.3.5. Stage of Disease
- 15.3.6. Patient Demographics
- 15.3.7. End-Users
- 15.3.8. Country
- 15.3.8.1. Germany
- 15.3.8.2. United Kingdom
- 15.3.8.3. France
- 15.3.8.4. Italy
- 15.3.8.5. Spain
- 15.3.8.6. Netherlands
- 15.3.8.7. Nordic Countries
- 15.3.8.8. Poland
- 15.3.8.9. Russia & CIS
- 15.3.8.10. Rest of Europe
- 15.4. Germany Neurogenerative Disorders Market
- 15.4.1. Country Segmental Analysis
- 15.4.2. Disease Type
- 15.4.3. Drug Class
- 15.4.4. Route of Administration
- 15.4.5. Mechanism of Action
- 15.4.6. Stage of Disease
- 15.4.7. Patient Demographics
- 15.4.8. End-Users
- 15.5. United Kingdom Neurogenerative Disorders Market
- 15.5.1. Country Segmental Analysis
- 15.5.2. Disease Type
- 15.5.3. Drug Class
- 15.5.4. Route of Administration
- 15.5.5. Mechanism of Action
- 15.5.6. Stage of Disease
- 15.5.7. Patient Demographics
- 15.5.8. End-Users
- 15.6. France Neurogenerative Disorders Market
- 15.6.1. Country Segmental Analysis
- 15.6.2. Disease Type
- 15.6.3. Drug Class
- 15.6.4. Route of Administration
- 15.6.5. Mechanism of Action
- 15.6.6. Stage of Disease
- 15.6.7. Patient Demographics
- 15.6.8. End-Users
- 15.7. Italy Neurogenerative Disorders Market
- 15.7.1. Country Segmental Analysis
- 15.7.2. Disease Type
- 15.7.3. Drug Class
- 15.7.4. Route of Administration
- 15.7.5. Mechanism of Action
- 15.7.6. Stage of Disease
- 15.7.7. Patient Demographics
- 15.7.8. End-Users
- 15.8. Spain Neurogenerative Disorders Market
- 15.8.1. Country Segmental Analysis
- 15.8.2. Disease Type
- 15.8.3. Drug Class
- 15.8.4. Route of Administration
- 15.8.5. Mechanism of Action
- 15.8.6. Stage of Disease
- 15.8.7. Patient Demographics
- 15.8.8. End-Users
- 15.9. Netherlands Neurogenerative Disorders Market
- 15.9.1. Country Segmental Analysis
- 15.9.2. Disease Type
- 15.9.3. Drug Class
- 15.9.4. Route of Administration
- 15.9.5. Mechanism of Action
- 15.9.6. Stage of Disease
- 15.9.7. Patient Demographics
- 15.9.8. End-Users
- 15.10. Nordic Countries Neurogenerative Disorders Market
- 15.10.1. Country Segmental Analysis
- 15.10.2. Disease Type
- 15.10.3. Drug Class
- 15.10.4. Route of Administration
- 15.10.5. Mechanism of Action
- 15.10.6. Stage of Disease
- 15.10.7. Patient Demographics
- 15.10.8. End-Users
- 15.11. Poland Neurogenerative Disorders Market
- 15.11.1. Country Segmental Analysis
- 15.11.2. Disease Type
- 15.11.3. Drug Class
- 15.11.4. Route of Administration
- 15.11.5. Mechanism of Action
- 15.11.6. Stage of Disease
- 15.11.7. Patient Demographics
- 15.11.8. End-Users
- 15.12. Russia & CIS Neurogenerative Disorders Market
- 15.12.1. Country Segmental Analysis
- 15.12.2. Disease Type
- 15.12.3. Drug Class
- 15.12.4. Route of Administration
- 15.12.5. Mechanism of Action
- 15.12.6. Stage of Disease
- 15.12.7. Patient Demographics
- 15.12.8. End-Users
- 15.13. Rest of Europe Neurogenerative Disorders Market
- 15.13.1. Country Segmental Analysis
- 15.13.2. Disease Type
- 15.13.3. Drug Class
- 15.13.4. Route of Administration
- 15.13.5. Mechanism of Action
- 15.13.6. Stage of Disease
- 15.13.7. Patient Demographics
- 15.13.8. End-Users
- 16. Asia Pacific Neurogenerative Disorders Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. Asia Pacific Neurogenerative Disorders Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 16.3.1. Disease Type
- 16.3.2. Drug Class
- 16.3.3. Route of Administration
- 16.3.4. Mechanism of Action
- 16.3.5. Stage of Disease
- 16.3.6. Patient Demographics
- 16.3.7. End-Users
- 16.3.8. Country
- 16.3.8.1. China
- 16.3.8.2. India
- 16.3.8.3. Japan
- 16.3.8.4. South Korea
- 16.3.8.5. Australia and New Zealand
- 16.3.8.6. Indonesia
- 16.3.8.7. Malaysia
- 16.3.8.8. Thailand
- 16.3.8.9. Vietnam
- 16.3.8.10. Rest of Asia Pacific
- 16.4. China Neurogenerative Disorders Market
- 16.4.1. Country Segmental Analysis
- 16.4.2. Disease Type
- 16.4.3. Drug Class
- 16.4.4. Route of Administration
- 16.4.5. Mechanism of Action
- 16.4.6. Stage of Disease
- 16.4.7. Patient Demographics
- 16.4.8. End-Users
- 16.5. India Neurogenerative Disorders Market
- 16.5.1. Country Segmental Analysis
- 16.5.2. Disease Type
- 16.5.3. Drug Class
- 16.5.4. Route of Administration
- 16.5.5. Mechanism of Action
- 16.5.6. Stage of Disease
- 16.5.7. Patient Demographics
- 16.5.8. End-Users
- 16.6. Japan Neurogenerative Disorders Market
- 16.6.1. Country Segmental Analysis
- 16.6.2. Disease Type
- 16.6.3. Drug Class
- 16.6.4. Route of Administration
- 16.6.5. Mechanism of Action
- 16.6.6. Stage of Disease
- 16.6.7. Patient Demographics
- 16.6.8. End-Users
- 16.7. South Korea Neurogenerative Disorders Market
- 16.7.1. Country Segmental Analysis
- 16.7.2. Disease Type
- 16.7.3. Drug Class
- 16.7.4. Route of Administration
- 16.7.5. Mechanism of Action
- 16.7.6. Stage of Disease
- 16.7.7. Patient Demographics
- 16.7.8. End-Users
- 16.8. Australia and New Zealand Neurogenerative Disorders Market
- 16.8.1. Country Segmental Analysis
- 16.8.2. Disease Type
- 16.8.3. Drug Class
- 16.8.4. Route of Administration
- 16.8.5. Mechanism of Action
- 16.8.6. Stage of Disease
- 16.8.7. Patient Demographics
- 16.8.8. End-Users
- 16.9. Indonesia Neurogenerative Disorders Market
- 16.9.1. Country Segmental Analysis
- 16.9.2. Disease Type
- 16.9.3. Drug Class
- 16.9.4. Route of Administration
- 16.9.5. Mechanism of Action
- 16.9.6. Stage of Disease
- 16.9.7. Patient Demographics
- 16.9.8. End-Users
- 16.10. Malaysia Neurogenerative Disorders Market
- 16.10.1. Country Segmental Analysis
- 16.10.2. Disease Type
- 16.10.3. Drug Class
- 16.10.4. Route of Administration
- 16.10.5. Mechanism of Action
- 16.10.6. Stage of Disease
- 16.10.7. Patient Demographics
- 16.10.8. End-Users
- 16.11. Thailand Neurogenerative Disorders Market
- 16.11.1. Country Segmental Analysis
- 16.11.2. Disease Type
- 16.11.3. Drug Class
- 16.11.4. Route of Administration
- 16.11.5. Mechanism of Action
- 16.11.6. Stage of Disease
- 16.11.7. Patient Demographics
- 16.11.8. End-Users
- 16.12. Vietnam Neurogenerative Disorders Market
- 16.12.1. Country Segmental Analysis
- 16.12.2. Disease Type
- 16.12.3. Drug Class
- 16.12.4. Route of Administration
- 16.12.5. Mechanism of Action
- 16.12.6. Stage of Disease
- 16.12.7. Patient Demographics
- 16.12.8. End-Users
- 16.13. Rest of Asia Pacific Neurogenerative Disorders Market
- 16.13.1. Country Segmental Analysis
- 16.13.2. Disease Type
- 16.13.3. Drug Class
- 16.13.4. Route of Administration
- 16.13.5. Mechanism of Action
- 16.13.6. Stage of Disease
- 16.13.7. Patient Demographics
- 16.13.8. End-Users
- 17. Middle East Neurogenerative Disorders Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Middle East Neurogenerative Disorders Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 17.3.1. Disease Type
- 17.3.2. Drug Class
- 17.3.3. Route of Administration
- 17.3.4. Mechanism of Action
- 17.3.5. Stage of Disease
- 17.3.6. Patient Demographics
- 17.3.7. End-Users
- 17.3.8. Country
- 17.3.8.1. Turkey
- 17.3.8.2. UAE
- 17.3.8.3. Saudi Arabia
- 17.3.8.4. Israel
- 17.3.8.5. Rest of Middle East
- 17.4. Turkey Neurogenerative Disorders Market
- 17.4.1. Country Segmental Analysis
- 17.4.2. Disease Type
- 17.4.3. Drug Class
- 17.4.4. Route of Administration
- 17.4.5. Mechanism of Action
- 17.4.6. Stage of Disease
- 17.4.7. Patient Demographics
- 17.4.8. End-Users
- 17.5. UAE Neurogenerative Disorders Market
- 17.5.1. Country Segmental Analysis
- 17.5.2. Disease Type
- 17.5.3. Drug Class
- 17.5.4. Route of Administration
- 17.5.5. Mechanism of Action
- 17.5.6. Stage of Disease
- 17.5.7. Patient Demographics
- 17.5.8. End-Users
- 17.6. Saudi Arabia Neurogenerative Disorders Market
- 17.6.1. Country Segmental Analysis
- 17.6.2. Disease Type
- 17.6.3. Drug Class
- 17.6.4. Route of Administration
- 17.6.5. Mechanism of Action
- 17.6.6. Stage of Disease
- 17.6.7. Patient Demographics
- 17.6.8. End-Users
- 17.7. Israel Neurogenerative Disorders Market
- 17.7.1. Country Segmental Analysis
- 17.7.2. Disease Type
- 17.7.3. Drug Class
- 17.7.4. Route of Administration
- 17.7.5. Mechanism of Action
- 17.7.6. Stage of Disease
- 17.7.7. Patient Demographics
- 17.7.8. End-Users
- 17.8. Rest of Middle East Neurogenerative Disorders Market
- 17.8.1. Country Segmental Analysis
- 17.8.2. Disease Type
- 17.8.3. Drug Class
- 17.8.4. Route of Administration
- 17.8.5. Mechanism of Action
- 17.8.6. Stage of Disease
- 17.8.7. Patient Demographics
- 17.8.8. End-Users
- 18. Africa Neurogenerative Disorders Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. Africa Neurogenerative Disorders Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 18.3.1. Disease Type
- 18.3.2. Drug Class
- 18.3.3. Route of Administration
- 18.3.4. Mechanism of Action
- 18.3.5. Stage of Disease
- 18.3.6. Patient Demographics
- 18.3.7. End-Users
- 18.3.8. Country
- 18.3.8.1. South Africa
- 18.3.8.2. Egypt
- 18.3.8.3. Nigeria
- 18.3.8.4. Algeria
- 18.3.8.5. Rest of Africa
- 18.4. South Africa Neurogenerative Disorders Market
- 18.4.1. Country Segmental Analysis
- 18.4.2. Disease Type
- 18.4.3. Drug Class
- 18.4.4. Route of Administration
- 18.4.5. Mechanism of Action
- 18.4.6. Stage of Disease
- 18.4.7. Patient Demographics
- 18.4.8. End-Users
- 18.5. Egypt Neurogenerative Disorders Market
- 18.5.1. Country Segmental Analysis
- 18.5.2. Disease Type
- 18.5.3. Drug Class
- 18.5.4. Route of Administration
- 18.5.5. Mechanism of Action
- 18.5.6. Stage of Disease
- 18.5.7. Patient Demographics
- 18.5.8. End-Users
- 18.6. Nigeria Neurogenerative Disorders Market
- 18.6.1. Country Segmental Analysis
- 18.6.2. Disease Type
- 18.6.3. Drug Class
- 18.6.4. Route of Administration
- 18.6.5. Mechanism of Action
- 18.6.6. Stage of Disease
- 18.6.7. Patient Demographics
- 18.6.8. End-Users
- 18.7. Algeria Neurogenerative Disorders Market
- 18.7.1. Country Segmental Analysis
- 18.7.2. Disease Type
- 18.7.3. Drug Class
- 18.7.4. Route of Administration
- 18.7.5. Mechanism of Action
- 18.7.6. Stage of Disease
- 18.7.7. Patient Demographics
- 18.7.8. End-Users
- 18.8. Rest of Africa Neurogenerative Disorders Market
- 18.8.1. Country Segmental Analysis
- 18.8.2. Disease Type
- 18.8.3. Drug Class
- 18.8.4. Route of Administration
- 18.8.5. Mechanism of Action
- 18.8.6. Stage of Disease
- 18.8.7. Patient Demographics
- 18.8.8. End-Users
- 19. South America Neurogenerative Disorders Market Analysis
- 19.1. Key Segment Analysis
- 19.2. Regional Snapshot
- 19.3. South America Neurogenerative Disorders Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 19.3.1. Disease Type
- 19.3.2. Drug Class
- 19.3.3. Route of Administration
- 19.3.4. Mechanism of Action
- 19.3.5. Stage of Disease
- 19.3.6. Patient Demographics
- 19.3.7. End-Users
- 19.3.8. Country
- 19.3.8.1. Brazil
- 19.3.8.2. Argentina
- 19.3.8.3. Rest of South America
- 19.4. Brazil Neurogenerative Disorders Market
- 19.4.1. Country Segmental Analysis
- 19.4.2. Disease Type
- 19.4.3. Drug Class
- 19.4.4. Route of Administration
- 19.4.5. Mechanism of Action
- 19.4.6. Stage of Disease
- 19.4.7. Patient Demographics
- 19.4.8. End-Users
- 19.5. Argentina Neurogenerative Disorders Market
- 19.5.1. Country Segmental Analysis
- 19.5.2. Disease Type
- 19.5.3. Drug Class
- 19.5.4. Route of Administration
- 19.5.5. Mechanism of Action
- 19.5.6. Stage of Disease
- 19.5.7. Patient Demographics
- 19.5.8. End-Users
- 19.6. Rest of South America Neurogenerative Disorders Market
- 19.6.1. Country Segmental Analysis
- 19.6.2. Disease Type
- 19.6.3. Drug Class
- 19.6.4. Route of Administration
- 19.6.5. Mechanism of Action
- 19.6.6. Stage of Disease
- 19.6.7. Patient Demographics
- 19.6.8. End-Users
- 20. Key Players/ Company Profile
- 20.1. AbbVie Inc.
- 20.1.1. Company Details/ Overview
- 20.1.2. Company Financials
- 20.1.3. Key Customers and Competitors
- 20.1.4. Business/ Industry Portfolio
- 20.1.5. Product Portfolio/ Specification Details
- 20.1.6. Pricing Data
- 20.1.7. Strategic Overview
- 20.1.8. Recent Developments
- 20.2. Acorda Therapeutics, Inc.
- 20.3. Amneal Pharmaceuticals LLC
- 20.4. AstraZeneca plc
- 20.5. Biogen Inc.
- 20.6. Boehringer Ingelheim International GmbH
- 20.7. Bristol-Myers Squibb Company
- 20.8. Eisai Co., Ltd.
- 20.9. Eli Lilly and Company
- 20.10. GlaxoSmithKline plc
- 20.11. Johnson & Johnson
- 20.12. Lundbeck A/S
- 20.13. Merck & Co., Inc.
- 20.14. Novartis AG
- 20.15. Orion Corporation
- 20.16. Pfizer Inc.
- 20.17. Roche Holding AG
- 20.18. Sanofi S.A.
- 20.19. Teva Pharmaceutical Industries Ltd.
- 20.20. UCB S.A.
- 20.21. Other Key Players
- 20.1. AbbVie Inc.
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography
Our research design integrates both demand-side and supply-side analysis through a balanced combination of primary and secondary research methodologies. By utilizing both bottom-up and top-down approaches alongside rigorous data triangulation methods, we deliver robust market intelligence that supports strategic decision-making.
MarketGenics' comprehensive research design framework ensures the delivery of accurate, reliable, and actionable market intelligence. Through the integration of multiple research approaches, rigorous validation processes, and expert analysis, we provide our clients with the insights needed to make informed strategic decisions and capitalize on market opportunities.
MarketGenics leverages a dedicated industry panel of experts and a comprehensive suite of paid databases to effectively collect, consolidate, and analyze market intelligence.
Our approach has consistently proven to be reliable and effective in generating accurate market insights, identifying key industry trends, and uncovering emerging business opportunities.
Through both primary and secondary research, we capture and analyze critical company-level data such as manufacturing footprints, including technical centers, R&D facilities, sales offices, and headquarters.
Our expert panel further enhances our ability to estimate market size for specific brands based on validated field-level intelligence.
Our data mining techniques incorporate both parametric and non-parametric methods, allowing for structured data collection, sorting, processing, and cleaning.
Demand projections are derived from large-scale data sets analyzed through proprietary algorithms, culminating in robust and reliable market sizing.
The bottom-up approach builds market estimates by starting with the smallest addressable market units and systematically aggregating them to create comprehensive market size projections.
This method begins with specific, granular data points and builds upward to create the complete market landscape.
Customer Analysis → Segmental Analysis → Geographical Analysis
The top-down approach starts with the broadest possible market data and systematically narrows it down through a series of filters and assumptions to arrive at specific market segments or opportunities.
This method begins with the big picture and works downward to increasingly specific market slices.
TAM → SAM → SOM
While analysing the market, we extensively study secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and commercial report. Secondary sources that we utilize are not only the public sources, but it is combination of Open Source, Associations, Paid Databases, MG Repository & Knowledgebase and Others.
- Company websites, annual reports, financial reports, broker reports, and investor presentations
- National government documents, statistical databases and reports
- News articles, press releases and web-casts specific to the companies operating in the market, Magazines, reports, and others
- We gather information from commercial data sources for deriving company specific data such as segmental revenue, share for geography, product revenue, and others
- Internal and external proprietary databases (industry-specific), relevant patent, and regulatory databases
- Governing Bodies, Government Organizations
- Relevant Authorities, Country-specific Associations for Industries
We also employ the model mapping approach to estimate the product level market data through the players product portfolio
Primary research/ interviews is vital in analyzing the market. Most of the cases involves paid primary interviews. Primary sources includes primary interviews through e-mail interactions, telephonic interviews, surveys as well as face-to-face interviews with the different stakeholders across the value chain including several industry experts.
| Type of Respondents | Number of Primaries |
|---|---|
| Tier 2/3 Suppliers | ~20 |
| Tier 1 Suppliers | ~25 |
| End-users | ~25 |
| Industry Expert/ Panel/ Consultant | ~30 |
| Total | ~100 |
MG Knowledgebase
• Repository of industry blog, newsletter and case studies
• Online platform covering detailed market reports, and company profiles
- Historical Trends – Past market patterns, cycles, and major events that shaped how markets behave over time. Understanding past trends helps predict future behavior.
- Industry Factors – Specific characteristics of the industry like structure, regulations, and innovation cycles that affect market dynamics.
- Macroeconomic Factors – Economic conditions like GDP growth, inflation, and employment rates that affect how much money people have to spend.
- Demographic Factors – Population characteristics like age, income, and location that determine who can buy your product.
- Technology Factors – How quickly people adopt new technology and how much technology infrastructure exists.
- Regulatory Factors – Government rules, laws, and policies that can help or restrict market growth.
- Competitive Factors – Analyzing competition structure such as degree of competition and bargaining power of buyers and suppliers.
Multiple Regression Analysis
- Identify and quantify factors that drive market changes
- Statistical modeling to establish relationships between market drivers and outcomes
Time Series Analysis – Seasonal Patterns
- Understand regular cyclical patterns in market demand
- Advanced statistical techniques to separate trend, seasonal, and irregular components
Time Series Analysis – Trend Analysis
- Identify underlying market growth patterns and momentum
- Statistical analysis of historical data to project future trends
Expert Opinion – Expert Interviews
- Gather deep industry insights and contextual understanding
- In-depth interviews with key industry stakeholders
Multi-Scenario Development
- Prepare for uncertainty by modeling different possible futures
- Creating optimistic, pessimistic, and most likely scenarios
Time Series Analysis – Moving Averages
- Sophisticated forecasting for complex time series data
- Auto-regressive integrated moving average models with seasonal components
Econometric Models
- Apply economic theory to market forecasting
- Sophisticated economic models that account for market interactions
Expert Opinion – Delphi Method
- Harness collective wisdom of industry experts
- Structured, multi-round expert consultation process
Monte Carlo Simulation
- Quantify uncertainty and probability distributions
- Thousands of simulations with varying input parameters
Our research framework is built upon the fundamental principle of validating market intelligence from both demand and supply perspectives. This dual-sided approach ensures comprehensive market understanding and reduces the risk of single-source bias.
Demand-Side Analysis: We understand end-user/application behavior, preferences, and market needs along with the penetration of the product for specific application.
Supply-Side Analysis: We estimate overall market revenue, analyze the segmental share along with industry capacity, competitive landscape, and market structure.
Data triangulation is a validation technique that uses multiple methods, sources, or perspectives to examine the same research question, thereby increasing the credibility and reliability of research findings. In market research, triangulation serves as a quality assurance mechanism that helps identify and minimize bias, validate assumptions, and ensure accuracy in market estimates.
- Data Source Triangulation – Using multiple data sources to examine the same phenomenon
- Methodological Triangulation – Using multiple research methods to study the same research question
- Investigator Triangulation – Using multiple researchers or analysts to examine the same data
- Theoretical Triangulation – Using multiple theoretical perspectives to interpret the same data
